JPRN-UMIN000010435招募中2 期
A clinical phase-II trial of neoadjuvant chemoradiotherapy with S-1 and Gemcitabine for locally advanced pancreatic cancer (PerSeUS-GP02) - PerSeUS-GP02
PerSeUS: Perpetual Study estimated-by United Sections in gifu0 个研究点目标入组 40 人开始时间: 2013年4月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Lung fibrosis or interstitial pneumonia. (should be confirmed by chest radiograph or CT within 28 days before the entry) 2. Watery diarrhea or chronic diarrhea 3. Regular use of Fenitoin, Warfarin or Frucitocin 4. Pleural effusion or ascites 5. Active infection 6. Other malignancies 7. Active gastroduodenal ulcer 8. Serious comorbid illness (heart failure, renal failure, liver failure, intestinal paralysis, uncontrolled diabetes, etc) 9. Serious mental disorder 10. Serious drug allergy 11. Pregnancy, breast feeding, or women who desire to preserve fecundity. Men who want his partner to be pregnant. 12. Patients who were judged inappropriate for the entry to this study by the investigators
研究者
相似试验
已完成
2 期
A clinical phase-II trial of neoadjuvant chemoradiation therapy using S-1 for locally advanced pancreatic cancer (PerSeUS-GP-01)ocally advanced pancreatic cancerJPRN-UMIN000002176PerSeUS-GP40
招募中
不适用
A phase II clinical trial of neoadjuvant chemoradiation therapy for pancreatic ductal adenocarcinomapancreatic cancerJPRN-UMIN000035232Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University50
尚未招募
1 期
A phase II clinical trial of neoadjyvant chemoradiation therapy using Gemcitabine combined with IMRT for borderline resectable pancreatic cancerborderline resectable pancreatic cancerJPRN-UMIN000010113Hepato-pamcreato-biliary Surgery and Transplantation, Graduate School of Medicine and Faculty of Medicine KyotoUniversity37
尚未招募
不适用
Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamideHER2 negative primary breast cancerJPRN-UMIN000019787Dept of breast oncology50
进行中（未招募）
不适用
Phase I/II-Studie zur neoadjuvanten Chemotherapie mit nicht-pegyliertem liposomalem Doxorubicin, Paclitaxel und Lapatinib bei Patientinnen mit HER2-überexprimierenden, primärem MammakarzinomeEUCTR2007-000924-42-DESana Klinikum Lichtenberg